Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04345900 · ClinicalTrials.gov registry record · Phase 2
Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2
A Phase 2 study, sponsored by BeyondSpring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT04345900 is a Phase 2 study that has completed, run by BeyondSpring Pharmaceuticals. The registered enrollment target is 55 participants.
The verdict
NCT04345900, a Phase 2 study, has completed, sponsored by BeyondSpring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count was to be assessed at baseline (prior to Cycle 1 docetaxel dose) and during Cycle 1 on Days 1, 2, 6, 7, 8, 9, 10, and 15 (pre-dose on dosing days; times equivalent to pre dose on other days).
Interventions
- DRUG Pegfilgrastim
- DRUG Plinabulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2018-04-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04345900
The ClinicalTrials.gov registry entry for NCT04345900 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeyondSpring Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pegfilgrastim is the first listed.
NCT04345900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04345900 about?
NCT04345900 is a clinical study titled "Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2". To assess the duration of severe neutropenia (DSN) in treatment Cycle 1 in patients treated with docetaxel (75 mg/m2) + plinabulin (5, 10, or 20 mg/m2) or with docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count was to be assessed at baseline (prior to Cycle 1 docetaxel dose) and during C...
What is the current status of trial NCT04345900?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2017-04-05. Estimated completion is 2018-04-20.
What interventions are being tested in trial NCT04345900?
The interventions under investigation include: Pegfilgrastim (DRUG), Plinabulin (DRUG).
Who is sponsoring clinical trial NCT04345900?
This trial is sponsored by BeyondSpring Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.